Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
R107314-100mg | 100mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $90.90 |
Antioxidant polyphenol with a multitude of biological activities
Synonyms | resveratrol|501-36-0|trans-resveratrol|3,4',5-Trihydroxystilbene|(E)-5-(4-Hydroxystyryl)benzene-1,3-diol|3,5,4'-Trihydroxystilbene|(E)-resveratrol|Resvida|3,4',5-Stilbenetriol|5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol|3,4',5-Trihydroxy-trans-stil |
---|---|
Specifications & Purity | Moligand™, analytical standard |
Biochemical and Physiological Mechanisms | Resveratrol is a phenolic phytoalexin found in grape skin and other plants. Resveratrol produced neurotrophic effects on cultured DA neurons. Resveratrol could attenuate oxidant-induced mitochondrial damage in embryonic rat cardiomyocytes by inactivating |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | analytical standard, Moligand™ |
Action Type | AGONIST, ANTAGONIST, INHIBITOR |
Mechanism of action | Inhibitor of COX-2;Agonist of TAS2R14;Antagonist of Peroxisome proliferator-activated receptor-γ |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol |
---|---|
INCHI | InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+ |
InChi Key | LUKBXSAWLPMMSZ-OWOJBTEDSA-N |
Canonical SMILES | C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O |
Isomeric SMILES | C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O |
WGK Germany | 3 |
RTECS | CZ8987000 |
Alternate CAS | 501-36-0 |
PubChem CID | 445154 |
NSC Number | 327430 |
MeSH Entry Terms | 3,4',5-stilbenetriol;3,4',5-Trihydroxystilbene;3,5,4'-trihydroxystilbene;cis Resveratrol;cis-resveratrol;resveratrol;Resveratrol 3 sulfate;Resveratrol, (Z)-;resveratrol-3-sulfate;SRT 501;SRT-501;SRT501;trans Resveratrol;trans Resveratrol 3 O sulfate;trans |
Molecular Weight | 228.24 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
H1617086 | Certificate of Analysis | Dec 20, 2023 | R107314 |
Melt Point(°C) | 267 °C |
---|
Pictogram(s) | GHS07 |
---|---|
Signal | Warning |
Hazard Statements | H319:Causes serious eye irritation |
Precautionary Statements | P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do - continue rinsing. P280:Wear protective gloves/protective clothing/eye protection/face protection. P264+P265:Wash hands [and …] thoroughly after handling. Do not touch eyes. P337+P317:If eye irritation persists: Get medical help. |
WGK Germany | 3 |
RTECS | CZ8987000 |
Merck Index | 8158 |
1. Kode A, Rajendrasozhan S, Caito S, Yang SR, Megson IL, Rahman I. (2008) Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells.. Am J Physiol Lung Cell Mol Physiol, 294 (3): (L478-88). [PMID:18162601] |
2. Ungvari Z, Bagi Z, Feher A, Recchia FA, Sonntag WE, Pearson K, de Cabo R, Csiszar A. (2010) Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2.. Am J Physiol Heart Circ Physiol, 299 (1): (H18-24). [PMID:20418481] |
3. Rizvi SI, Pandey KB. (2010) Activation of the erythrocyte plasma membrane redox system by resveratrol: a possible mechanism for antioxidant properties.. Pharmacol Rep, 62 (4): (726-32). [PMID:20885013] |
4. Kelsey NA, Wilkins HM, Linseman DA. (2010) Nutraceutical antioxidants as novel neuroprotective agents.. Molecules, 15 (11): (7792-814). [PMID:21060289] |
5. Speciale A, Chirafisi J, Saija A, Cimino F. (2011) Nutritional antioxidants and adaptive cell responses: an update.. Curr Mol Med, 11 (9): (770-89). [PMID:21999148] |
6. Voloshyna I, Hai O, Littlefield MJ, Carsons S, Reiss AB. (2013) Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPARγ and adenosine.. Eur J Pharmacol, 698 (1-3): (299-309). [PMID:23041272] |
7. St John SE, Jensen KC, Kang S, Chen Y, Calamini B, Mesecar AD, Lipton MA. (2013) Design, synthesis, biological and structural evaluation of functionalized resveratrol analogues as inhibitors of quinone reductase 2.. Bioorg Med Chem, 21 (19): (6022-37). [PMID:23953689] |
8. Zordoky BN, Robertson IM, Dyck JR. (2015) Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases.. Biochim Biophys Acta, 1852 (6): (1155-77). [PMID:25451966] |
9. Ma T, Tan MS, Yu JT, Tan L. (2014) Resveratrol as a therapeutic agent for Alzheimer's disease.. Biomed Res Int, 2014 (3): (350516). [PMID:25525597] |
10. Park EJ, Pezzuto JM. (2015) The pharmacology of resveratrol in animals and humans.. Biochim Biophys Acta, 1852 (6): (1071-113). [PMID:25652123] |
11. Vahid F, Zand H, Nosrat-Mirshekarlou E, Najafi R, Hekmatdoost A. (2015) The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review.. Gene, 562 (1): (8-15). [PMID:25701602] |
12. Han G, Xia J, Gao J, Inagaki Y, Tang W, Kokudo N. (2015) Anti-tumor effects and cellular mechanisms of resveratrol.. Drug Discov Ther, 9 (1): (1-12). [PMID:25788047] |
13. Britton RG, Kovoor C, Brown K. (2015) Direct molecular targets of resveratrol: identifying key interactions to unlock complex mechanisms.. Ann N Y Acad Sci, 1348 (1): (124-33). [PMID:26099829] |
14. Fu W, Zhuang W, Zhou S, Wang X. (2015) Plant-derived neuroprotective agents in Parkinson's disease.. Am J Transl Res, 7 (7): (1189-202). [PMID:26328004] |
15. Gong WH, Zhao N, Zhang ZM, Zhang YX, Yan L, Li JB. (2017) The inhibitory effect of resveratrol on COX-2 expression in human colorectal cancer: a promising therapeutic strategy.. Eur Rev Med Pharmacol Sci, 21 (5): (1136-1143). [PMID:28338176] |
16. Bariani MV, Correa F, Leishman E, Domínguez Rubio AP, Arias A, Stern A, Bradshaw HB, Franchi AM. (2017) Resveratrol protects from lipopolysaccharide-induced inflammation in the uterus and prevents experimental preterm birth.. Mol Hum Reprod, 23 (8): (571-581). [PMID:28810692] |
17. Kong F, Zhang R, Zhao X, Zheng G, Wang Z, Wang P. (2017) Resveratrol raisesin vitroanticancer effects of paclitaxel in NSCLC cell line A549 through COX-2 expression.. Korean J Physiol Pharmacol, 21 (5): (465-474). [PMID:28883751] |
18. Buhrmann C, Popper B, Aggarwal BB, Shakibaei M. (2017) Resveratrol downregulates inflammatory pathway activated by lymphotoxin α (TNF-β) in articular chondrocytes: Comparison with TNF-α.. PLoS ONE, 12 (11): (e0186993). [PMID:29095837] |
19. Afewerky HK et al.. (2022) Sodium-calcium exchanger isoform-3 targeted Withania somnifera (L.) Dunal therapeutic intervention ameliorates cognition in the 5xFAD mouse model of Alzheimer's disease.. Sci Rep, 12 (1537). [PMID:35087161] |
20. Yao ZQ et al.. (2018) A novel small-molecule activator of Sirtuin-1 induces autophagic cell death/mitophagy as a potential therapeutic strategy in glioblastoma.. Cell Death Dis, 9 (7): (767). [PMID:29991742] |
21. Campo VA. (2017) Comparative effects of histone deacetylases inhibitors and resveratrol on Trypanosoma cruzi replication, differentiation, infectivity and gene expression.. Int J Parasitol Drugs Drug Resist, 7 (23-33). [PMID:28038431] |
22. Nevoral J et al.. (2019) Epigenetic and non-epigenetic mode of SIRT1 action during oocyte meiosis progression.. J Anim Sci Biotechnol, 10 (67). [PMID:31413827] |
23. Guo D et al.. (2018) Resveratrol protects early brain injury after subarachnoid hemorrhage by activating autophagy and inhibiting apoptosis mediated by the Akt/mTOR pathway.. Neuroreport, 29 (5): (368-379). [PMID:29360689] |
24. Adamkova K et al.. (2017) SIRT1-dependent modulation of methylation and acetylation of histone H3 on lysine 9 (H3K9) in the zygotic pronuclei improves porcine embryo development.. J Anim Sci Biotechnol, 8 (83). [PMID:29118980] |